Clinical trial · Interventional
Efficiency of Presurgical Basal Cell Carcinoma Margin Mapping
Efficiency of Presurgical Basal Cell Carcinoma Margin Mapping Using Optical Coherence Tomography
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Funding exhausted. Sufficient data already collected.
Summary
Brief summary (as posted)
This Interventional Randomised Controlled study is intended to establish that presurgical margin mapping of BCCs with OCT results in a reduction of the number of MMS surgery stages without adversely impacting clinical outcome, resulting in shorter patient stays and more efficient use of surgical and operating room resources.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Basal Cell | Basal Cell Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| OCT Mapped | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- OCT Mapped arm
- description
- OCT is used to map the tumour margins as the first stage MMS estimate
- interventionNames
- Other: OCT Mapped
- type
- NO_INTERVENTION
- label
- Control arm
- description
- Standard MMS is performed
Primary outcomes (1)
- measure
- Average number of Mohs stages
- timeFrame
- 1 day
- description
- Is the average number of Mohs stages \< 1.4 with a 95% confidence level. (P \< 0.025)
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with biopsy-proven BCCs who have been referred for MMS Exclusion Criteria: * Patients with BCCs larger than 6 cm2
References
Publications (0)
Data not yet available